TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors
In Vitro
TG6-10-1 robustly blocks prostaglandin E2 (PGE2) (10 μM)-induced cAMP accumulation in a concentration-dependent manner in SH-SY5Y cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
TG6-10-1 (5 mg/kg; i.p.; 4-30 hours) improves survival, accelerates recovery of lost weight, and improves functional recovery following status epilepticus (SE) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice (pilocarpine-induced SE) Dosage: 5 mg/kg Administration: Intraperitoneal injection; 4, 21, 30 hours Result: A significant increase in survival and accelerating the recovery of lost weight in post-SE mice.
